Bacteria still kill around six million people every year, and existing vaccines fail to protect against many of these infections. The BactiVac network aims to break the bottlenecks that prevent new bacterial vaccines from reaching the people who need them most, particularly in low and middle-income countries (LMICs). Scientific hurdles—such as deciding what antigen to include in a shot—and economic neglect, where commercial viability is too low to attract industry investment, both stall development. The network will connect UK researchers with partners in LMICs, industry, and developing-world manufacturers, offering training grants, small catalyst projects, and an annual meeting to share expertise. If successful, BactiVac will accelerate the pipeline from laboratory idea to licensed vaccine, reducing deaths from bacterial disease and slowing the rise of antimicrobial resistance. The project also includes an advocacy programme targeting governments, the WHO, and the public to raise awareness of the value of bacterial vaccines. This is a coordination and capacity-building network, not a laboratory research project, but it aims to remove the structural barriers that keep promising vaccines from ever being made.
View original technical description
Vaccines save millions of lives every year and typically work silently in the background, promoting the body's ability to kill the pathogen before an infection is established. Despite this, bacteria still cause around six millions deaths/year in humans and many more in animals, with people in low and middle-income countries (LMICs) disproportionately affected. Worryingly, as anti-microbial resistance (AMR) increases, the number of deaths from infection will rise with devastating personal and economic consequences. One reason bacteria can cause so much harm is because there are many different diseases caused by bacteria for which there is either no vaccine or the existing vaccine does not provide complete protection. New vaccines against bacterial infections will help people in all countries, but most prominently in LMICs. Unfortunately, there are many barriers that currently prevent such vaccines from being developed. These barriers can be for scientific reasons, such as what to put in the vaccine, or economic issues, such as neglect due to lack of commercial viability. To help overcome these barriers and deliver new vaccines to where they are needed, a network is needed that enables scientists, clinicians and companies from around the world to come together and share their skills and knowledge. This is what the 'BactiVac' bacterial vaccinology network for human and animal vaccines will achieve. The network will be centred in the UK, harnessing the considerable strength already present in the UK in disciplines related to bacterial vaccinology, including immunology, epidemiology, systems biology, clinical trials and support for vaccine licensure. Crucially, the network will build on and foster new partnerships with LMICs, with industry, and manufacturers in developing countries. BactiVac will support bacterial vaccine development from when the idea is conceived to when it is licensed for use in humans or animals, particularly helping at those points where most potential vaccines flounder. The network will achieve these ambitions by combining a number of approaches. 1. The network will identify which diseases in LMICs caused by bacteria should be prioritised and how the broad vaccine community can be helped to make new vaccines that prevent them. 2. We will provide training grants, particularly for members from LMICs, to learn the skills needed to grow the research and industrial base in vaccinology. 3. By interconnecting the diverse experience and skills within the membership, we will facilitate new partnerships and sharing of information, supported by the creation of a member directory, a BactiVac website and regular newsfeeds, along with an annual networking meeting. 4. To encourage these new partnerships, the network will support small scale 'catalyst' projects through an open annual competition. These projects will grow new areas and partnerships to encourage larger scale funding, accelerate vaccine development and to help overcome the bottlenecks that prevent vaccines going from an idea to a product. 5. Underpinning all of these focused activities BactiVac will provide an advocacy programme that promotes the importance, need and value of vaccines to bacterial infections. This programme will work with the general public, governments and ministries of health, and non-governmental organisations, including key stake-holders in global health policy, such as the WHO and other funding organisations. Collectively, this will lead to a growth in research and development of new vaccines against bacterial infections and improve lives across the world.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know